Selected research
Industry Research
Antibody Drug CDMO Service Industry Research Report 2026
Market perspective
The global Antibody Drug CDMO Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antibody Drug CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antibody Drug CDMO Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antibody Drug CDMO Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antibody Drug CDMO Service include Abzena, AGC Biologics, Axplora, Batavia Biosciences, ChemExpress, FUJIFILM, GTP Bioways, Halix and MYCENAX, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antibody Drug CDMO Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antibody Drug CDMO Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antibody Drug CDMO Service Market by Company
Abzena
AGC Biologics
Axplora
Batavia Biosciences
ChemExpress
FUJIFILM
GTP Bioways
Halix
MYCENAX
WuXi Biologics
ProBio
Samsung Biologics
Sigma-Aldrich
Antibody Drug CDMO Service Segment by Type
Customized Service
Lab-based Service
Others
Antibody Drug CDMO Service Segment by Application
Antibody Drug Conjugates
Monoclonal Antibodies
Others
Antibody Drug CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antibody Drug CDMO Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Customized Service
- Lab-based Service
- Others
Applications
- Antibody Drug Conjugates
- Monoclonal Antibodies
- Others
Companies covered
- Abzena
- AGC Biologics
- Axplora
- Batavia Biosciences
- ChemExpress
- FUJIFILM
- GTP Bioways
- Halix
- MYCENAX
- WuXi Biologics
- ProBio
- Samsung Biologics
- Sigma-Aldrich
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antibody Drug CDMO Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Customized Service
- 2.2.3 Lab-based Service
- 2.2.4 Others
- 2.3 Antibody Drug CDMO Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Antibody Drug Conjugates
- 2.3.3 Monoclonal Antibodies
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Antibody Drug CDMO Service Breakdown Data by Type
- 3.1 Global Antibody Drug CDMO Service Historic Market Size by Type (2021-2026)
- 3.2 Global Antibody Drug CDMO Service Forecasted Market Size by Type (2027-2032)
4 Antibody Drug CDMO Service Breakdown Data by Application
- 4.1 Global Antibody Drug CDMO Service Historic Market Size by Application (2021-2026)
- 4.2 Global Antibody Drug CDMO Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antibody Drug CDMO Service Market Perspective (2021-2032)
- 5.2 Global Antibody Drug CDMO Service Growth Trends by Region
- 5.2.1 Global Antibody Drug CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antibody Drug CDMO Service Historic Market Size by Region (2021-2026)
- 5.2.3 Antibody Drug CDMO Service Forecasted Market Size by Region (2027-2032)
- 5.3 Antibody Drug CDMO Service Market Dynamics
- 5.3.1 Antibody Drug CDMO Service Industry Trends
- 5.3.2 Antibody Drug CDMO Service Market Drivers
- 5.3.3 Antibody Drug CDMO Service Market Challenges
- 5.3.4 Antibody Drug CDMO Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antibody Drug CDMO Service Players by Revenue
- 6.1.1 Global Top Antibody Drug CDMO Service Players by Revenue (2021-2026)
- 6.1.2 Global Antibody Drug CDMO Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Antibody Drug CDMO Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antibody Drug CDMO Service Head Office and Area Served
- 6.4 Global Antibody Drug CDMO Service Players, Product Type & Application
- 6.5 Global Antibody Drug CDMO Service Manufacturers Established Date
- 6.6 Global Antibody Drug CDMO Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antibody Drug CDMO Service Market Size (2021-2032)
- 7.2 North America Antibody Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 7.4 North America Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antibody Drug CDMO Service Market Size (2021-2032)
- 8.2 Europe Antibody Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 8.4 Europe Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antibody Drug CDMO Service Market Size (2021-2032)
- 9.2 Asia-Pacific Antibody Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antibody Drug CDMO Service Market Size (2021-2032)
- 10.2 South America Antibody Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 10.4 South America Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antibody Drug CDMO Service Market Size (2021-2032)
- 11.2 Middle East & Africa Antibody Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abzena
- 12.1.1 Abzena Company Information
- 12.1.2 Abzena Business Overview
- 12.1.3 Abzena Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.1.4 Abzena Antibody Drug CDMO Service Product Portfolio
- 12.1.5 Abzena Recent Developments
- 12.2 AGC Biologics
- 12.2.1 AGC Biologics Company Information
- 12.2.2 AGC Biologics Business Overview
- 12.2.3 AGC Biologics Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.2.4 AGC Biologics Antibody Drug CDMO Service Product Portfolio
- 12.2.5 AGC Biologics Recent Developments
- 12.3 Axplora
- 12.3.1 Axplora Company Information
- 12.3.2 Axplora Business Overview
- 12.3.3 Axplora Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.3.4 Axplora Antibody Drug CDMO Service Product Portfolio
- 12.3.5 Axplora Recent Developments
- 12.4 Batavia Biosciences
- 12.4.1 Batavia Biosciences Company Information
- 12.4.2 Batavia Biosciences Business Overview
- 12.4.3 Batavia Biosciences Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.4.4 Batavia Biosciences Antibody Drug CDMO Service Product Portfolio
- 12.4.5 Batavia Biosciences Recent Developments
- 12.5 ChemExpress
- 12.5.1 ChemExpress Company Information
- 12.5.2 ChemExpress Business Overview
- 12.5.3 ChemExpress Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.5.4 ChemExpress Antibody Drug CDMO Service Product Portfolio
- 12.5.5 ChemExpress Recent Developments
- 12.6 FUJIFILM
- 12.6.1 FUJIFILM Company Information
- 12.6.2 FUJIFILM Business Overview
- 12.6.3 FUJIFILM Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.6.4 FUJIFILM Antibody Drug CDMO Service Product Portfolio
- 12.6.5 FUJIFILM Recent Developments
- 12.7 GTP Bioways
- 12.7.1 GTP Bioways Company Information
- 12.7.2 GTP Bioways Business Overview
- 12.7.3 GTP Bioways Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.7.4 GTP Bioways Antibody Drug CDMO Service Product Portfolio
- 12.7.5 GTP Bioways Recent Developments
- 12.8 Halix
- 12.8.1 Halix Company Information
- 12.8.2 Halix Business Overview
- 12.8.3 Halix Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.8.4 Halix Antibody Drug CDMO Service Product Portfolio
- 12.8.5 Halix Recent Developments
- 12.9 MYCENAX
- 12.9.1 MYCENAX Company Information
- 12.9.2 MYCENAX Business Overview
- 12.9.3 MYCENAX Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.9.4 MYCENAX Antibody Drug CDMO Service Product Portfolio
- 12.9.5 MYCENAX Recent Developments
- 12.10 WuXi Biologics
- 12.10.1 WuXi Biologics Company Information
- 12.10.2 WuXi Biologics Business Overview
- 12.10.3 WuXi Biologics Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.10.4 WuXi Biologics Antibody Drug CDMO Service Product Portfolio
- 12.10.5 WuXi Biologics Recent Developments
- 12.11 ProBio
- 12.11.1 ProBio Company Information
- 12.11.2 ProBio Business Overview
- 12.11.3 ProBio Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.11.4 ProBio Antibody Drug CDMO Service Product Portfolio
- 12.11.5 ProBio Recent Developments
- 12.12 Samsung Biologics
- 12.12.1 Samsung Biologics Company Information
- 12.12.2 Samsung Biologics Business Overview
- 12.12.3 Samsung Biologics Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.12.4 Samsung Biologics Antibody Drug CDMO Service Product Portfolio
- 12.12.5 Samsung Biologics Recent Developments
- 12.13 Sigma-Aldrich
- 12.13.1 Sigma-Aldrich Company Information
- 12.13.2 Sigma-Aldrich Business Overview
- 12.13.3 Sigma-Aldrich Revenue in Antibody Drug CDMO Service Business (2021-2026)
- 12.13.4 Sigma-Aldrich Antibody Drug CDMO Service Product Portfolio
- 12.13.5 Sigma-Aldrich Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst